Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
June 15, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
June 08, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
May 23, 2022 07:00 ET
|
Evoke Pharma, Inc.
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety...
Patient Experience Survey Reported Positive Findings for GIMOTI®
May 18, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and...
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports First Quarter 2022 Financial Results
May 10, 2022 16:05 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
May 03, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
April 26, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
April 19, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
March 10, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...